Cow's milk-specific immunoglobulin E (sIgE) (sIgE)

Cow's milk-specific immunoglobulin E (IgE) is a specialized antibody produced by the immune system that recognizes and binds to specific proteins found in bovine milk, primarily casein, alpha-lactalbumin, and beta-lactoglobulin [1]. In individuals with cow's milk allergy, these IgE antibodies are sensitized and bound to high-affinity FcεRI receptors on mast cells and basophils [2]. Upon re-exposure to milk allergens, the cross-linking of these IgE molecules triggers the immediate release of inflammatory mediators, such as histamine and leukotrienes, resulting in clinical symptoms that can range from mild urticaria to severe, systemic anaphylaxis [1, 2]. As a therapeutic target, cow's milk-specific IgE is addressed through pharmacological agents like Omalizumab, which neutralizes circulating IgE to prevent the allergic cascade, and through allergen-specific immunotherapy aimed at inducing immunological tolerance [3]. Measurement of these specific IgE levels serves as a vital diagnostic biomarker and a prognostic indicator for the resolution of milk allergy in pediatric populations [1, 4].

Other names

Milk-specific IgEBovine milk-specific IgEAnti-cow's milk IgEIgE to cow's milk proteinssIgE to cow's milk

Monoclonal antibodies like Omalizumab bind to the Cε3 domain of the IgE molecule, which is the site of binding for both high-affinity (FcεRI) and low-affinity (FcεRII) receptors, thereby neutralizing free IgE and downregulating receptor expression on effector cells [3].